AUGMENTIN 4:1 ORAL SUSPENSION
2145
Approved/Revised 03-Jan-2006
Material
SDS Number
Version 15
GlaxoSmithKline, Corporate Environment, Health & Safety
Company Name
980 Great West Road
+44-20-8047-5000
UK General Information:
+44-1865-407333
Transport Emergency (EU)
+1-612-221-3999, Ext 221
Medical Emergency
US number, available 24 hours
Information and Advice:
Multi-language response
Brentford, Middlesex TW8 9GS UK
+1-888-825-5249
US General Information:
+1-703-527-3887
Transport Emergency (non EU)
US number, available 24 hours
Multi-language response
One Franklin Plaza, 200 N 16th Street
GlaxoSmithKline, Corporate Environment, Health & Safety
Philadelphia, PA 19102-1225 US
Percentage
CAS RN
Ingredients
14.5 to 22.2
61336-70-7
AMOXICILLIN TRIHYDRATE
3.6 to 5.6
61177-45-5
POTASSIUM CLAVULANATE
72.2 to 81.9
Unassigned
NON-HAZARDOUS INGREDIENTS
Fire and Explosion
Assume that this product is capable of sustaining combustion.
SAFETY DATA SHEET
1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE
COMPANY/UNDERTAKING
2. COMPOSITION / INFORMATION ON INGREDIENTS
3. HAZARDS IDENTIFICATION
Synonyms
AUGMENTIN 125 MG/5 ML SUSPENSION * AUGMENTIN 156.25 MG/5 ML
SUSPENSION * AUGMENTIN 250 MG/5 ML SUSPENSION * AUGMENTIN
312.5 MG/5 ML SUSPENSION * CLAVULIN-125F SUSPENSION *
CLAVULIN-250F SUSPENSION * CLAMOXYL SUSPENSION 125 MG *
CLAMOXYL SUSPENSION 250 MG * NDC NO. 0029-6085-22 * NDC NO.
0029-6085-23 * NDC NO. 0029-6085-39 * NDC NO. 0029-6090-22 * NDC NO.
0029-6090-23 * NDC NO. 0029-6090-39 * AMOXYCILLIN TRIHYDRATE AND
POTASSIUM CLAVULANATE, FORMULATED PRODUCT
Material
AUGMENTIN 4:1 ORAL SUSPENSION
Page 1 / 6
AUGMENTIN 4:1 ORAL SUSPENSION
2145
Approved/Revised 03-Jan-2006
Material
SDS Number
Version 15
Health
Exposure might occur via skin; eyes; ingestion; inhalation.
May produce allergic skin reactions.
Respiratory allergen.
Possible effects of overexposure in the workplace include: symptoms of
hypersensitivity (such as skin rash, hives, itching, and difficulty breathing);
nausea; vomiting; di